Home › Acute Biphenotypic Leukemia › Illinois
Acute Biphenotypic Leukemia clinical trials in Illinois
7 studies for Acute Biphenotypic Leukemia are looking for participants at sites in Illinois.
Cities in Illinois
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Lurie Children's Hospital-Chicago, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Advocate Children's Hospital-Oak Lawn, Oak Lawn
- and 3 more
RecruitingPhase 2
365 Days · All sexes · Updated Sep 25, 2026 · NCT06317662A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- The University of Chicago Medical Center, Chicago
RecruitingPhase 1/2
30 Days · All sexes · Updated Sep 16, 2026 · NCT04065399The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- and 6 more
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- and 5 more
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Illinois at Chicago Cancer Center, Chicago
RecruitingPhase 1/2
Ages 12 to 95 · All sexes · Updated Apr 15, 2026 · NCT04329728Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Ann & Robert H Lurie Children's Hospital of Chicago, Chicago
RecruitingPhase 1
Ages 1 to 40 · All sexes · Updated Mar 12, 2026 · NCT05292664Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.